Meropenem: An updated review of its use in the management of intra-abdominal infections

Drugs

Volumn 60, Issue 3, 2000, Pages 619-646

  Lowe, M N ^a   Lamb, H M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFOTAXIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; ICI 213689; MEROPENEM; METRONIDAZOLE; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; POSTANTIBIOTIC EFFECT; SEIZURE;

NEGIBACTERIA; POSIBACTERIA;

EID: 0033769761     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00010     Document Type: Article

References (108)

1. Management of complicated intra-abdominal infections
2. General guidelines for the evaluation of new anti-infective drugs for the treatment of intra-abdominal and pelvic infections: Evaluation of new anti-infective drugs for the treatment of intra-abdominal infections
3. Management of intraabdominal infections. The case for intra-operative cultures and comprehensive broad-spectrum antibiotic coverage
4. A proposed classification of intra-abdominal infections: Stratification of etiology and risk for future therapeutic trials
5. Antibiotic trials in intra-abdominal infections: A critical evaluation of study design and outcome reporting
6. Guidelines for clinical care: Anti-infective agents for intra-abdominal infection. A surgical infection society policy statement
7. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy
8. The challenge of intra-abdominal infections
9. Antibiotics and the abdomen
10. Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
11. Management of febrile episodes in neutropenic patients: Defining the role of meropenem
12. Meropenem: A review of its use in patients in intensive care
13. Meropenem versus imipenem/citastatin in the treatment of intra-abdominal infections
14. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide
15. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers
16. Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997
17. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
18. Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18 632 aerobic bacteria tested in 92 German centers
19. European results (1997-99) from the MYSTIC study
20. In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems
21. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998
22. Acquired carbapenemases
23. Worldwide emergence of carbapenem-resistant Acinetobacter spp
24. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak
25. Antimicrobial susceptibility of viridans group streptococci
26. In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study
27. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity
28. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group
29. Trends in antimicrobial resistance of the Bacteroides fragilis group: A 20-year study at a medical center in Buenos Aires, Argentina
30. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995-1996, with comparison of resistance trends from 1990 to 1996
31. In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria
32. In vitro activity of three carbapenems (biapenem, imipenem and meropenem) and some other antibiotics on anaerobic bacteria
33. Carbapenem-hydrolysing β-lactamases
34. Carbapenemases
35. Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa
36. Mechanisms of resistance to the carbapenems
37. Markedly different rates and resistance profiles exhibited by seven commonly used and newer β-lactams on the selection of resistant variants of Enterobacter cloacae
38. In vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem
39. Effect of meropenem on the intestinal microflora
40. Secondary bacterial peritonitis: The biologic basis of treatment
41. Inoculum effect
42. Meropenem: In-vitro activity and kinetics against organisms of the Bacteroides fragilis group
43. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
44. In vitro studies of meropenem
45. Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine
46. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations
47. Pharmacodynamic effects of meropenem on Gram-negative bacteria
48. Post-antibiotic effect of carbapenems against Pseudomonas aeruginosa
49. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men
50. Pharmacokinetics of meropenem in patients with intra-abdominal infections
51. The pharmacokinetics of meropenem in surgical patients with moderate or severe infections
52. Meropenem clinical pharmacokinetics
53. The pharmacokinetics of meropenem
54. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients
55. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care
56. A compilation of meropenem tissue distribution data
57. Intraperitoneal penetration of meropenem
58. Meropenem pharmacokinetics and penetration into an inflammatory exudate
59. A study of penetration of meropenem into bile using endoscopic retrograde cholangiography
60. 14C-meropenem in man
61. Pharmacokinetics of meropenem in patients with liver disease
62. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections
63. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections
64. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients
65. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit
66. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: Results of a prospective, randomized, multicentre trial
67. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections
68. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery
69. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections requiring surgery
70. Meropenem (Merrem) versus imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study
71. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections
72. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections
73. Meropenem versus cefotaxime-based therapy for the initial treatment of infants and children hospitalized with non-CNS infections
74. Safety and efficacy of meropenem in hospitalized children: Randomized comparison with cefotaxime, alone and combined with metronidazole or amikacin
75. Meropenem in the treatment of patients with surgical infections
76. Clinical study of meropenem in the surgical field
77. Meropenem in abdominal skin and soft tissue infections in the field of surgery
78. Pharmacokinetics and clinical efficacy of meropenem in surgical infections
79. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis
80. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double-blind clinical trial
81. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
82. Meropenem versus imipenem/cilastatin for the treatment of serious bacterial infections at ICU
83. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients
84. Impact of anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections
85. Meropenem: Clinical response in relation to in vitro susceptibility
86. The pharmacoeconomics of meropenem versus imipenem/cilastatin
87. Cost analysis of infusion versus injection delivery of imipenem/cilastatin and meropenem
88. An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin
89. Meropenem: A pharmacoeconomic review of its use in serious infections
90. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections
91. Safety profile of meropenem: A review of nearly 5,000 patients treated with meropenem
92. Safety profile of meropenem: International clinical experience based on the first 3125 patients treated with meropenem
93. Meropenem in elderly and renally impaired patients
94. Clinically important aspects of carbapenem safety
95. Differentiating meropenem and imipenem/cilastatin
96. Efficacy and safety of imipenem/cilastatin: A review of worldwide clinical experience
97. Imipenem/cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections
98. Carbapenems in clinical practice: A guide to their use in serious infection
99. Rational antibiotic therapy for intra-abdominal infections
100. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections
101. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections
102. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections